中国药物经济学2023，Vol.18Issue(12)：96-99,4.DOI:10.12010/j.issn.1673-5846.2023.12.022
奥希替尼对比一二代表皮生长因子受体-酪氨酸激酶抑制剂在非小细胞肺癌脑转移中的治疗优势
The Therapeutic Advantage of Ohitinib in the Treatment of Non-small Cell Lung Cancer with Brain Metastases compared with One or Two Representative Skin Growth Factor Receptor-Tyrosine Kinase Inhibitors
摘要
Abstract
Objective To explore the therapeutic advantages of ocitinib versus one or two representative skin growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in non-small cell lung cancer(NSCLC)brain metastases.Methods Retrospective data analysis method was used to collect clinical data of patients taking gefitinib,afatinib,erlotinib and ocitinib in Jiangmen Central Hospital from January 2019 to February 2022.The duration from initial treatment to onset of brain metastases was compared between first and second generation EGFR-TKIs and ocitinib patients without brain metastases.Total metastasis diameter,disease control rate(DCR),median progression-free survival(PFS),objective response rate(ORR)were compared between first and second generation EGFR-TKIs and ocitinib patients with brain metastases.Results The duration of brain metastases in patients receiving ocitinib with out brain metastases was significantly shorter than that in patients receiving first and second generation EGFR-TKIs,the difference was statistically significant(P＜0.05).The total diameter of brain metastases in the ocitinib group with brain metastases was significantly lower than that in the first and second generation EGFR-TKIs group,and the DCR,median PFS and ORR were significantly higher than those in the first and second generation EGFR-TKIs group,with statistical significance(P＜0.05).Conclusion Ocitinib can slow down the speed of brain metastasis in NSCLC patients,and effectively slow down the growth rate of mass in NSCLC patients with brain metastasis,and effectively improve the quality of life and survival time.关键词
奥希替尼/一二代表皮生长因子受体-酪氨酸激酶抑制剂/非小细胞肺癌/脑转移/治疗优势Key words
Osimertinib/One or two representative skin growth factor receptor-tyrosine kinase inhibitors/Non-small cell lung cancer/Brain metastases/Therapeutic advantage分类
医药卫生引用本文复制引用
余仲华,黄志贞,陈钦贤..奥希替尼对比一二代表皮生长因子受体-酪氨酸激酶抑制剂在非小细胞肺癌脑转移中的治疗优势[J].中国药物经济学,2023,18(12):96-99,4.基金项目
江门市科技计划项目(2022YL01079) （2022YL01079）
